- Home
- CUE vs CVM Comparison
CUE vs CVM Comparison
Compare CUE & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CVM
- Stock Information
- Founded
- CUE 2014
- CVM 1983
- Country
- CUE United States
- CVM United States
- Employees
- CUE N/A
- CVM N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CUE Health Care
- CVM Health Care
- Exchange
- CUE Nasdaq
- CVM Nasdaq
- Market Cap
- CUE 61.1M
- CVM 53.1M
- IPO Year
- CUE 2018
- CVM 1987
- Fundamental
- Price
- CUE $0.56
- CVM $6.20
- Analyst Decision
- CUE Strong Buy
- CVM
- Analyst Count
- CUE 2
- CVM 0
- Target Price
- CUE $3.00
- CVM N/A
- AVG Volume (30 Days)
- CUE 394.8K
- CVM 91.0K
- Earning Date
- CUE 11-12-2025
- CVM 08-14-2025
- Dividend Yield
- CUE N/A
- CVM N/A
- EPS Growth
- CUE N/A
- CVM N/A
- EPS
- CUE N/A
- CVM N/A
- Revenue
- CUE $7,100,000.00
- CVM N/A
- Revenue This Year
- CUE N/A
- CVM N/A
- Revenue Next Year
- CUE N/A
- CVM N/A
- P/E Ratio
- CUE N/A
- CVM N/A
- Revenue Growth
- CUE N/A
- CVM N/A
- 52 Week Low
- CUE $0.54
- CVM $1.98
- 52 Week High
- CUE $1.75
- CVM $32.70
- Technical
- Relative Strength Index (RSI)
- CUE 28.56
- CVM 32.52
- Support Level
- CUE $0.57
- CVM $6.50
- Resistance Level
- CUE $0.62
- CVM $6.89
- Average True Range (ATR)
- CUE 0.08
- CVM 0.46
- MACD
- CUE -0.01
- CVM -0.03
- Stochastic Oscillator
- CUE 0.53
- CVM 2.89
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.